Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ESSA Pharma Inc.EPIX · Entity 15763 | Chief Medical Officer | March 25, 2024 | March 28, 2024 |
| PUMA BIOTECHNOLOGY, INC.PBYI · Entity 5478 | Director | September 14, 2026 | September 17, 2026 |
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director | January 02, 2026 | January 06, 2026 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | January 12, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ESSA Pharma Inc.
Report date March 25, 2024 · Filed March 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.04 · Expires 2034-03-25 | Direct | 200,000 |
Reported balance
After 2024-03-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-25 · Grant · Acquired 200,000 · Balance 200,000 F1: Stock options vest and become exercisable over four years as follows: (i) 25% of the underlying shares vest one year after the grant date; and (ii) 75% of the remaining underlying shares vest in equal monthly installments over the following three years. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest and become exercisable over four years as follows: (i) 25% of the underlying shares vest one year after the grant date; and (ii) 75% of the remaining underlying shares vest in equal monthly installments over the following three years.
PUMA BIOTECHNOLOGY, INC.
Report date September 14, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,700 |
Ending reported balance
After 2026-09-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-14 · Exercise / conversion · Acquired 50,000 · Balance 118,850 Row 2 · 2026-09-14 · Sale · Disposed 62,150 · Balance 56,700 F1: Adoption date of referenced 10b5-1(c) plan is: 06-15-2026 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.03 to $9.2, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.93 · Expires 2032-07-28 | Direct | 50,000 |
Reported balance
After 2026-09-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-14 · Exercise / conversion · Disposed 50,000 · Balance 50,000 F3: The Stock Option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Adoption date of referenced 10b5-1(c) plan is: 06-15-2026
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.03 to $9.2, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: The Stock Option is fully vested.
Summit Therapeutics Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.52 · Expires 2036-01-02 | Direct | 35,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 35,000 · Balance 35,000 F2: Not applicable. F1: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.52 · Expires 2036-01-02 | Direct | 3,219 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 3,219 · Balance 3,219 F4: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $28,200. F3: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date.
F2: Not applicable.
F3: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date.
F4: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $28,200.
Zymeworks Inc.
Report date January 12, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.16 · Expires 2036-01-11 | Direct | 11,500 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 11,500 · Balance 11,500 F1: Stock options vest on January 12, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2027-01-12 | Direct | 7,700 |
Reported balance
After 2026-01-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-12 · Grant · Acquired 7,700 · Balance 7,700 F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3: RSUs vest on January 12, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on January 12, 2027.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
F3: RSUs vest on January 12, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 17, 2026 01:06 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | Exercise / conversionStock Option · Derivative | 50,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001437749-26-030593 · rdgdoc.xml · derivative · entry 3 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Stock Option is fully vested. Read SEC document |
| September 14, 2026 Filed Sep 17, 2026 01:06 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 62,150 | $9.12 | $566,994.45 |
DisclosureSEC source: 0001437749-26-030593 · rdgdoc.xml · nonDerivative · entry 2 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,700 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 06-15-2026 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.03 to $9.2, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 14, 2026 Filed Sep 17, 2026 01:06 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | Exercise / conversionCommon Stock | 50,000 | $2.93 | $146,500.00 |
DisclosureSEC source: 0001437749-26-030593 · rdgdoc.xml · nonDerivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2026 Filed Jun 16, 2026 00:07 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-020702 · rdgdoc.xml · nonDerivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,850 F1 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:54 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 7,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010856 · ownership.xml · derivative · entry 2 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2027-01-12 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3 · derivative.exercise_date: RSUs vest on January 12, 2027. F3 · derivative.expiration_date: RSUs vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:54 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-010856 · ownership.xml · derivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2036-01-11 F1 · derivative.exercise_date: Stock options vest on January 12, 2027. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 23:39 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 3,219 | $8.76 Strike: $17.52 | $28,198.44 |
DisclosureSEC source: 0001827015-26-000002 · wk-form4_1767742793.xml · derivative · entry 2 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,219 Underlying: Common Stock · 3,219 shares Expires 2036-01-02 F4 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $28,200. F3 · derivative.exercise_date: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 23:39 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $17.52 | Not disclosed |
DisclosureSEC source: 0001827015-26-000002 · wk-form4_1767742793.xml · derivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-01-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date. Read SEC document |
| July 18, 2025 Filed Jul 22, 2025 23:51 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 27,000 | $3.37 | $90,909.00 |
DisclosureSEC source: 0001437749-25-023268 · rdgdoc.xml · nonDerivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,850 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 03-11-2025 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.34 to $3.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 23:41 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 12,150 | $3.40 | $41,310.00 |
DisclosureSEC source: 0001437749-25-020711 · rdgdoc.xml · nonDerivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,850 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 03-11-2025 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.34 to $3.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 11, 2025 Filed Jun 14, 2025 00:10 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-020357 · rdgdoc.xml · nonDerivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,000 F1 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:17 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 3,073 | $9.18 Strike: $18.35 | $28,210.14 |
DisclosureSEC source: 0001599298-25-000026 · wk-form4_1736209060.xml · derivative · entry 2 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,073 Underlying: Common Stock · 3,073 shares Expires 2035-01-02 F4 · price: The option was issued to the reporting person pursuant to the Director Retainer Option Election Plan of issuer in lieu of retainer fees of $28,200. F3 · derivative.exercise_date: The option was granted on January 2, 2025. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the director remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:17 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $18.35 | Not disclosed |
DisclosureSEC source: 0001599298-25-000026 · wk-form4_1736209060.xml · derivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-01-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 2, 2025. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 23:01 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $13.06 | $0.00 |
DisclosureSEC source: 0000950170-24-135932 · ownership.xml · derivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2034-12-09 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 10, 2024. Read SEC document |
| June 18, 2024 Filed Jun 22, 2024 01:16 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-021012 · rdgdoc.xml · nonDerivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,000 F1 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| March 25, 2024 Filed Mar 28, 2024 12:25 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | GrantOptions · Derivative | 200,000 | $0.00 Strike: $9.04 | $0.00 |
DisclosureSEC source: 0000950172-24-000129 · form4.xml · derivative · entry 1 Cesano Alessandra · CIK 0001827015 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2034-03-25 F1 · derivative.exercise_date: Stock options vest and become exercisable over four years as follows: (i) 25% of the underlying shares vest one year after the grant date; and (ii) 75% of the remaining underlying shares vest in equal monthly installments over the following three years. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 23:15 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 74,000 | $0.00 Strike: $11.47 | $0.00 |
DisclosureSEC source: 0000950170-24-013427 · ownership.xml · derivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 74,000 shares Expires 2034-02-07 F1 · derivative.exercise_date: Stock options vest in 36 equal monthly installments starting one month after grant date of February 8, 2024. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:33 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 21,363 | $1.32 Strike: $2.64 | $28,199.16 |
DisclosureSEC source: 0001599298-24-000017 · wk-form4_1704404000.xml · derivative · entry 2 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,363 Underlying: Common Stock · 21,363 shares Expires 2034-01-02 F4 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $28,200. F3 · derivative.exercise_date: The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the director remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:33 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $2.64 | Not disclosed |
DisclosureSEC source: 0001599298-24-000017 · wk-form4_1704404000.xml · derivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-01-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-salaried director on each such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 00:10 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-017590 · rdgdoc.xml · nonDerivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 F1 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:17 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 16,350 | $1.67 Strike: $5.00 | $27,304.50 |
DisclosureSEC source: 0001827015-23-000003 · wf-form4_167295342532705.xml · derivative · entry 2 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,350 Underlying: Common Stock · 16,350 shares Expires 2033-01-03 F4 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $27,250. F3 · derivative.exercise_date: The option was issued on January 3, 2023. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the director remaining as a non-employee director on each such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:17 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001827015-23-000003 · wf-form4_167295342532705.xml · derivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-01-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 3, 2023. The shares underlying the option shall vest in four equal annual installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-employee director on each such vesting date. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 21:27 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 4,166 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001599298-22-000127 · wf-form4_166872044673174.xml · derivative · entry 2 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,166 Underlying: Common Stock · 4,166 shares Expires 2032-11-15 F2 · price: Not applicable. F3 · derivative.exercise_date: The option was granted on November 15, 2022 and represents a pro rata amount of the annual 25,000 option board grant based approximately on the number of days the Reporting Person is anticipated to serve as a director. The shares underlying the option are scheduled to vest in full on December 31, 2022. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 21:27 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 200,000 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001599298-22-000127 · wf-form4_166872044673174.xml · derivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-11-15 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on November 15, 2022. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on November 15, 2023. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 21:07 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 100,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001437749-22-018468 · rdgdoc.xml · derivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: COMMON STOCK · 100,000 shares Expires 2032-07-28 F1 · security: The vesting commencement date of the option is July 29, 2022 (the "Option Vesting Commencement Date"). Subject to the Reporting Person's continued service with the Issuer through the applicable vesting date, the option vests (i) on the first anniversary of the Option Vesting Commencement Date with respect to one-third (1/3rd) of the shares subject thereto and (ii) on each monthly anniversary of the Option Vesting Commencement Date thereafter with respect to an additional 1/36th of the shares subject thereto. F1 · derivative.exercise_date: The vesting commencement date of the option is July 29, 2022 (the "Option Vesting Commencement Date"). Subject to the Reporting Person's continued service with the Issuer through the applicable vesting date, the option vests (i) on the first anniversary of the Option Vesting Commencement Date with respect to one-third (1/3rd) of the shares subject thereto and (ii) on each monthly anniversary of the Option Vesting Commencement Date thereafter with respect to an additional 1/36th of the shares subject thereto. Read SEC document |
| June 29, 2022 Filed Nov 1, 2022 11:05 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-22-054967 · doc4.xml · derivative · entry 1 Cesano Alessandra · CIK 0001827015 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Shares · 90,000 shares Expires 2032-06-29 F1 · derivative.exercise_date: One-fourth vests after 12 months from the date of grant with the remaining three-fourths vesting in 36 equal installments with the first installment vesting at the end of the 13th month and subsequent installments vesting every one month anniversary thereafter. Read SEC document |
| December 11, 2020 Filed Jan 11, 2021 16:43 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | GrantStock Option (Right to Buy) · Derivative | 57,500 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002946 · doc4.xml · derivative · entry 1 Cesano Alessandra · CIK 0001827015 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Shares · 57,500 shares Expires 2030-12-11 F1 · derivative.exercise_date: 25% of the options vest after 12 months from the date of grant, and the remaining 75% vest in 36 equal installments with the first installment vesting at the end of the 13th month and subsequent installments vesting on every one month anniversary thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.